This Cookie Policy was last updated on Jun 17th, 2022 and applies to citizens and legal permanent residents of the European Economic Area and Switzerland
Our website, https://catenion.com/?lang=zh-hant (hereinafter: "the website") uses cookies and other related technologies (for convenience all technologies are referred to as "cookies"). Cookies are also placed by third parties we have engaged. In the document below we inform you about the use of cookies on our website.
A cookie is a small simple file that is sent along with pages of this website and stored by your browser on the hard drive of your computer or another device. The information stored therein may be returned to our servers or to the servers of the relevant third parties during a subsequent visit.
A script is a piece of program code that is used to make our website function properly and interactively. This code is executed on our server or on your device.
A web beacon (or a pixel tag) is a small, invisible piece of text or image on a website that is used to monitor traffic on a website. In order to do this, various data about you is stored using web beacons.
5.1 Technical or functional cookies
Some cookies ensure that certain parts of the website work properly and that your user preferences remain known. By placing functional cookies, we make it easier for you to visit our website. This way, you do not need to repeatedly enter the same information when visiting our website and, for example, the items remain in your shopping cart until you have paid. We may place these cookies without your consent.
5.2 Statistics cookies
We use statistics cookies to optimize the website experience for our users. With these statistics cookies we get insights in the usage of our website. We ask your permission to place statistics cookies.
5.3 Marketing/Tracking cookies
Marketing/Tracking cookies are cookies or any other form of local storage, used to create user profiles to display advertising or to track the user on this website or across several websites for similar marketing purposes.
5.4 Social media
On our website, we have included content from Twitter and LinkedIn to promote web pages (e.g. “like”, “pin”) or share (e.g. “tweet”) on social networks like Twitter and LinkedIn. This content is embedded with code derived from Twitter and LinkedIn and places cookies. This content might store and process certain information for personalized advertising.
Please read the privacy statement of these social networks (which can change regularly) to read what they do with your (personal) data which they process using these cookies. The data that is retrieved is anonymized as much as possible. Twitter and LinkedIn are located in the United States.
When you visit our website for the first time, we will show you a pop-up with an explanation about cookies. As soon as you click on "Accept", you consent to us using all cookies and plug-ins as described in the pop-up and this Cookie Policy. You can disable the use of cookies via your browser, but please note that our website may no longer work properly.
7.1 Manage your consent settings
You can use your internet browser to automatically or manually delete cookies. You can also specify that certain cookies may not be placed. Another option is to change the settings of your internet browser so that you receive a message each time a cookie is placed. For more information about these options, please refer to the instructions in the Help section of your browser.
Please note that our website may not work properly if all cookies are disabled. If you do delete the cookies in your browser, they will be placed again after your consent when you visit our websites again.
You have the following rights with respect to your personal data:
To exercise these rights, please contact us. Please refer to the contact details at the bottom of this Cookie Policy. If you have a complaint about how we handle your data, we would like to hear from you, but you also have the right to submit a complaint to the supervisory authority (the Data Protection Authority).
For questions and/or comments about our Cookie Policy and this statement, please contact us by using the following contact details:
Catenion
Münzstraße 18
10178 Berlin
Germany
Website:https://catenion.com/?lang=zh-hant
Email:moc.noinetac@ofni
Phone number: +49 30 20633356
This Cookie Policy was synchronized with cookiedatabase.org on Feb 01st, 2023
Arno Heuermann is a founding Partner of Catenion who lives in Berlin, Germany. Arno has ten years of experience as CEO and COO. He has managed companies in Germany, France and Luxemburg.
While working on his degrees, Arno founded a technical engineering office in 1994. He continued to follow the entrepreneurial path in 1998 by founding Biopsytec GmbH, a DNA diagnostics company focused on agriculture, heading the company for more than five years as Managing Director.
In 1999, he co–founded Epigenomics AG, a public biotech company focused on DNA methylation, later remaining as an advisor and member of the firm’s Supervisory Board.
In August 2000, Arno orchestrated the founding and financing of Biopsytec Holding AG, thus merging Genious SA and the QTL AG and Biopsytec GmbH. He managed Biopsytec Holding AG for the next three years before helping launch Catenion in 2003. Since that time, he has been Catenion’s chief operating officer.
Arno holds a diploma degree in process engineering from the Technical University of Applied Sciences in Berlin. In addition, Arno attended the Berlin business school for Industrial Engineering and Management.
He is experienced in the diverse practices of patent management and has made numerous successful inventions.
Arno Heuermann is married and has two children. He is a lover of classical music, country life and horseback riding.
Matthias Krings is a founding Partner of Catenion.
He has worked for international pharma, biotech and medtech organizations on a variety of topics. Matthias works with clients on developing corporate and R&D strategies, identifying new areas of opportunity, tailoring asset and company searches for BD&L and M&A, maximizing the value of existing assets through therapeutic expansion, and prioritizing R&D portfolios. Matthias is also resposible for the creation and delivery of bespoke client education programs in the Catenion Academy.
Before co-founding Catenion in 2003, Matthias was a consultant at Mercer Management Consulting (now Oliver Wyman) and later joined a strategy consulting boutique, Theron.
Matthias holds a diploma and a doctorate degree in Biology from the Ludwig-Maximilians University in Munich. His PhD work was supported by a scholarship from the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine. Matthias made significant scientific contributions to the field of human evolution (Krings et al., Cell 1997: Neandertal DNA Sequences and the Origin of Modern Humans).
Matthias lives in Munich & Berlin. He enjoys cooking, gardening, watersports and traveling.
Matthias co-authored Catenion’s Commentaries “Elements of Winning Strategies in R&D” and “Recombinant Portfolio Management – Recognizing and Enabling Innovation”. They are part of Catenion’s “Shaping Pharmaceutical Strategy” series that focuses on high-profile issues for the industry.
Christian Elze is a founding partner of Catenion and has been developing the company’s business in Japan since 2008. He holds a BSc from the London School of Economics and an MBA from Columbia University.
Christian is working with companies, universities and governments in the field of biomedical innovation. In his work, Christian is focusing on how emerging technologies and translational research are re-shaping the respective roles of funding agencies, investors, biopharma companies and academia in the research and development of new drugs.
Besides his consulting work, Christian frequently speaks about Emerging Technologies, Healthcare Reform, Pricing & Reimbursement, Biomedical Innovation, as well as Translational Research at industry conferences and universities in Japan, the US and Europe.
Christian is a fluent speaker of English, French, German, Italian, Portuguese, Russian and Spanish and lives with his family in London.
Markus 撰写了多篇 Catenion 评论文章，包括《Risk Profiles of Corporate Portfolio Strategies》以及《Elements of Winning Strategies in R&D》、《Recombinant Innovation Management (RIM) – How to Stimulate Breakthrough Innovation within Large R&D Organisations》、《Recombinant Portfolio Management – Recognising and Enabling Innovation》。 他也与其他作者合着了《Zero Base R&D》和《The Challenge for Japan’s Pharmaceutical Top Twenty》。 所有这些都是Catenion的 「塑造医药战略」（Shaping Pharmaceutical Strategy）系列的一部分，该系列关注的是行业中备受瞩目的问题。
Markus Thunecke 是 Catenion 的创始资深合伙人，居住在德国柏林。 Markus 于1997年在美世咨询公司开始了他的顾问生涯，之后加入了一家战略咨询精品公司 Theron，并于2003年成立了 Catenion。
Markus 已帮助了全球制药和医疗产品行业的众多客户创造竞争优势。 除了制定战略方面的工作，Markus 还擅长开发尖端的分析工具并将其与组织发展能力相结合。 Markus 是 Catenion 的一些投资组合管理和风险评估的专有工具的开发者。 在最近的工作中，Markus 帮助了客户制定和调整他们的研发战略，检视审查他们的发现和开发组合，并创建促进创新的组织模式。
Markus 经常在有关研发战略和组合管理的会议上发表演说。
他拥有海德堡大学的生物化学博士学位，期间他建立了阿尔茨海默病的转基因动物模型。 他也在德国先灵公司（Schering AG）有三年的中枢神经系统领域的研究经验。